U.S. OKs Lupin generic of Pfizer nerve pain drug
(Reuters) - India's Lupin Ltd said it won U.S. approval for a generic version of Pfizer Inc's big-selling Lyrica nerve pain treatment.
A spokesman for Lupin said it has not yet launched its version of Lyrica, which is also known as pregabalin.
Lyrica tallied U.S. sales of about $1.8 billion for the year ended in March, Lupin said, citing data from IMS Health Inc.
(Reporting by Lewis Krauskopf; Editing by Gerald E. McCormick)
- Hong Kong police use pepper spray to disperse pro-democracy protesters |
- Putin calls for talks on east Ukraine 'statehood'; rebels fire on ship |
- Dozens arrested at Made in America music festival in Los Angeles
- Pakistani protesters push closer to PM house, force TV off the air |
- Israel claims West Bank land for possible settlement use, draws U.S. rebuke